Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een onderzoeksstudie naar hoe goed Concizumab voor u werkt als u hemofilie A of B heeft met of zonder remmers (Explorer10)

17 september 2026 bijgewerkt door: Novo Nordisk A/S

Open-label onderzoek naar de werkzaamheid, veiligheid en farmacokinetiek van concizumab-profylaxe bij kinderen jonger dan 12 jaar met hemofilie A of B met of zonder remmers

This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.

Participants will have to inject the study medicine every day under the skin with a pen-injector.

The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.

Studie Overzicht

Toestand

Actief, niet wervend

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

153

Fase

  • Fase 3

Uitgebreide toegang

Niet meer beschikbaar buiten de klinische proef. Zie uitgebreid toegangsrecord.

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Algiers, Algerije, 16000
        • Haematology and Blood Bank Department
      • Constantine, Algerije, 25000
        • CHU Constantine BEN BADIS/ Hematology department
      • Banja Luka, Bosnië-Herzegovina, 78000
        • University Clinical Center of Republic Srpska (545)
      • Tuzla, Bosnië-Herzegovina, 75000
        • University Clinical Centre Tuzla
      • Plovdiv, Bulgarije, 4002
        • UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
      • Sofia, Bulgarije, 1527
        • UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
      • Varna, Bulgarije, 9010
        • UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
    • British Columbia
      • Vancouver, British Columbia, Canada, V6H 3V4
        • BC Children's Hospital
    • Ontario
      • Hamilton, Ontario, Canada, L8N 3Z5
        • McMaster Children's Hospital
      • Tallinn, Estland, 13419
        • Tallinn Children's Hospital
      • Chambéry, Frankrijk, 73000
        • Centre Hospitalier Metropole Savoie
      • Le Kremlin-Bicêtre, Frankrijk, 94275
        • Ap-Hp-Hopital de Bicetre-1
      • Paris, Frankrijk, 75015
        • AP-HP-HOPITAL NECKER_Service d'hématologie
      • Athens, Griekenland, GR-11527
        • Aghia Sophia Childrens' Hospital
      • Thessaloniki, Griekenland, GR 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
      • Thessaloniki, Griekenland, 54642
        • 'Ippokrateio' General Hospital of Thessaloniki
    • Assam
      • Guwahati, Assam, Indië, 781032
        • Guwahati Medical College
    • Gujarat
      • Surat, Gujarat, Indië, 395002
        • Nirmal Hospital Pvt. Ltd.
    • Maharashtra
      • Kolhāpur, Maharashtra, Indië, 416005
        • SSSH_Dept. of Clinical Haematology & Haemato Oncology
      • Mumbai, Maharashtra, Indië, 400012
        • Seth GS Medical College & KEM Hospital
      • Mumbai, Maharashtra, Indië, 400022
        • K.J Somaiya Hospital and Research Centre
      • Mumbai, Maharashtra, Indië, 400066
        • MCGM - Comprehensive Thalassemia Care
      • Pune, Maharashtra, Indië, 411004
        • Sahyadri Super Speciality Hospital
    • Odisha
      • Cuttack, Odisha, Indië, 753007
        • S.C.B. Medical College
    • Rajasthan
      • Jaipur, Rajasthan, Indië, 302004
        • J K Lon Hospital
    • Uttar Pradesh
      • Noida, Uttar Pradesh, Indië, 201303
        • Post Graduate Institute of Child Health
    • Uttart Pradesh
      • Lucknow, Uttart Pradesh, Indië, 226014
        • SGPGI
      • Catania, Italië, 95123
        • A.O.U policlinico "G. Rodolico-San Marco"
      • Florence, Italië, 50134
        • Dipartimento di Ematologia Univ. Firenze
      • Padova, Italië, 35128
        • Azienda Ospedaliera di Padova _
      • Parma, Italië, 43126
        • Azienda Ospedaliera-Universitaria Parma
      • Kanagawa, Japan, 216-8511
        • St. Marianna University School of Medicine Hospital_Pediatrics
      • Saitama, Japan, 330-8777
        • Saitama Children's Med Centre_Hematology-Oncology
      • Beirut, Libanon, 961
        • Saint George Hospital University Medical Center
      • Tripoli, Libanon, 1434
        • Hospital Nini
      • Vilnius, Litouwen, LT-08406
        • Centre of Oncology and Hematology, Vilnius University
    • Kuala Lumpur
      • Kampung Baru, Kuala Lumpur, Maleisië, 50300
        • Hospital Tunku Azizah
    • Pulau Pinang
      • George Town, Pulau Pinang, Maleisië, 10450
        • Hospital Pulau Pinang
    • Sarawak
      • Kuching, Sarawak, Maleisië, 93586
        • Sarawak General Hospital
    • Terengganu
      • Kuala Terengganu, Terengganu, Maleisië, 20400
        • Hospital Sultanah Nur Zahirah
      • Skopje, Noord-Macedonië, 1000
        • PHI University Clinic for Children's Diseases Skopje
      • Oslo, Noorwegen, 0372
        • Klinisk forskningspost
      • Gdansk, Polen, 80-952
        • Uniwersyteckie Centrum Kliniczne
      • Lublin, Polen, 20-093
        • Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
      • Warsaw, Polen, 02-091
        • Uniwersyteckie Centrum Kliniczne WUM
    • Lower Silesian Voivodeship
      • Wroclaw, Lower Silesian Voivodeship, Polen, 50-556
        • Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
      • Bucharest, Roemenië, 022328
        • Clinic of Haematology, Fundeni Clinical Institute
      • Cluj-Napoca, Roemenië, 400177
        • Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
      • Oradea, Roemenië, 410469
        • Spitalul Clinic Judetean De Urgenta Bihor
      • Barcelona, Spanje, 08035
        • Hospital Vall d'Hebron
      • Madrid, Spanje, 28046
        • Hospital Universitario La Paz
      • Málaga, Spanje, 29009
        • Hospital Regional Universitario de Málaga
    • Murcia
      • El Palmar, Murcia, Spanje, 30120
        • Hospital Virgen de la Arrixaca - Hematología
      • Bangkok, Thailand, 10400
        • Ramathibodi Hospital
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial Hospital_Bangkok_0
      • Bangkok, Thailand, 10700
        • Siriraj Hospital - Hematology and Oncology
      • Bangkok, Thailand, 10330
        • King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
    • Mueang Distirct,
      • Ubon Ratchathani, Mueang Distirct,, Thailand, 34000
        • Sunpasitthiprasong Hospital_Pediatrics Department
      • Adana, Turkije (Türkiye), 01130
        • Acibadem Adana Hastanesi
      • Adana, Turkije (Türkiye), 01130
        • Acıbadem Adana Hastanesi-Hematoloji
      • Izmir, Turkije (Türkiye), 35100
        • Ege Universitesi Tip Fakultesi
      • Izmir, Turkije (Türkiye), 35100
        • Ege Üniversitesi Hastanesi- Hematoloji
      • Samsun, Turkije (Türkiye), 55139
        • Ondokuz Mayis University Medical Faculty Ped. Haematology
      • Samsun, Turkije (Türkiye), 55139
        • Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
    • Beşevler/Ankara
      • Ankara, Beşevler/Ankara, Turkije (Türkiye), 06500
        • Gazi University
      • Ankara, Beşevler/Ankara, Turkije (Türkiye), 06500
        • Gazi Üniversitesi Hastanesi- Hematoloji
      • Birmingham, Verenigd Koninkrijk, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Verenigd Koninkrijk, BS2 8BJ
        • University Hospitals Bristol & Weston NHS Foundation Trust
      • London, Verenigd Koninkrijk, WC1N 3HR
        • Great Ormond Street Hospital for Children
      • London, Verenigd Koninkrijk, SE1 7EH
        • Evelina London Children's Hospital - Haemophilia
    • California
      • San Diego, California, Verenigde Staten, 92123
        • Rady Childrens Hosp San Diego
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • University of Colorado Hospital
    • Florida
      • Orlando, Florida, Verenigde Staten, 32806
        • Arnold Palmer Children's Hospital
      • Orlando, Florida, Verenigde Staten, 32827
        • Nemours Child Orlando Hem/Onc.
    • Georgia
      • Augusta, Georgia, Verenigde Staten, 30912
        • Augusta Univ/Childrens Hosp-GA
      • Savannah, Georgia, Verenigde Staten, 31404
        • Memorial Health University Medical Center
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60611
        • Childrens Hospital of Chicago
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46260
        • Indiana Hemophilia-Thromb Ctr
    • Louisiana
      • New Orleans, Louisiana, Verenigde Staten, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, Verenigde Staten, 70118
        • Children's Hosp-New Orleans
    • Missouri
      • Kansas City, Missouri, Verenigde Staten, 64108
        • The Children's Mercy Hospital
    • Nebraska
      • Omaha, Nebraska, Verenigde Staten, 68114
        • Children's Nebraska
    • North Carolina
      • Greenville, North Carolina, Verenigde Staten, 27834
        • ECU Sickle Cell Comp Clinic
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Verenigde Staten, 19134
        • St Christopher Hosp for Child
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37232
        • Monroe Carell Jr. Children's Hospital at Vanderbilt
    • Texas
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Cook Children's Hospital-Hematology-Oncology
      • Houston, Texas, Verenigde Staten, 77030
        • Texas Children's Hospital_Houston
    • Virginia
      • Charlottesville, Virginia, Verenigde Staten, 22908
        • Pediatrics Hematology/Oncology Clinic Battle Building
    • Gauteng
      • Parktown, Johannesburg, Gauteng, Zuid-Afrika, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Gothenburg, Zweden, 413 46
        • Sahlgrenska US - Koagulationscentrum

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.

  • Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.

  • For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.

  • For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)

    1. Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    2. Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
    3. Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
  • For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)

    1. Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
    2. Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
  • For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.

Exclusion Criteria:

  • Known or suspected hypersensitivity to study intervention or related products.
  • Known inherited or acquired coagulation disorder other than congenital haemophilia.
  • Ongoing or planned Immune Tolerance Induction treatment.
  • History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Concizumab-naïve patients

Concizumab-naïve participants below 12 years of age at the time of consent/assent

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Experimenteel: Patients coming from compassionate use

Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807

Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose.

Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of episode(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of patient(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)

Count of event(s)

From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: Week 32

Measured in ng/mL

Week 32
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: Week 32

Measured in nM

Week 32
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: Week 32

Measured in ng/mL

Week 32
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: Prior to the concizumab administration at week 20

Measured in ng/mL

Prior to the concizumab administration at week 20
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Tijdsspanne: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Measured in ng*hr/mL

From 0 to 24 hours where 0 is the time of the concizumab dose at week 20

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

24 maart 2022

Primaire voltooiing (Werkelijk)

21 april 2026

Studie voltooiing (Geschat)

2 november 2029

Studieregistratiedata

Eerst ingediend

15 november 2021

Eerst ingediend dat voldeed aan de QC-criteria

15 november 2021

Eerst geplaatst (Werkelijk)

26 november 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 september 2026

Laatste update ingediend die voldeed aan QC-criteria

17 september 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • NN7415-4616
  • U1111-1247-7330 (Andere identificatie: World Health Organization (WHO))
  • 2020-000504-11 (EudraCT-nummer)
  • jRCT2031220097 (Register-ID: JAPIC)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren